DelveInsight’s, “Esophageal Squamous Cell Carcinoma Pipeline Insight 2023,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Esophageal Squamous Cell Carcinoma pipeline landscape. It covers the Esophageal Squamous Cell Carcinoma pipeline drug profiles, including Esophageal Squamous Cell Carcinoma clinical trials and nonclinical stage products. It also covers the Esophageal Squamous Cell Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Esophageal Squamous Cell Carcinoma Emerging drugs, the Esophageal Squamous Cell Carcinoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Esophageal Squamous Cell Carcinoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Esophageal Squamous Cell Carcinoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Esophageal Squamous Cell Carcinoma clinical trials studies, Esophageal Squamous Cell Carcinoma NDA approvals (if any), and product development activities comprising the technology, Esophageal Squamous Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Esophageal Squamous Cell Carcinoma Pipeline Report
Request a sample and discover the recent breakthroughs happening in the Esophageal Squamous Cell Carcinoma Pipeline landscape @ Esophageal Squamous Cell Carcinoma Pipeline Outlook Report
Esophageal Squamous Cell Carcinoma Overview
Esophageal Squamous Cell Carcinoma is the most common form of esophageal cancer worldwide. Although it is no longer the most common form of esophageal carcinoma in Western societies, ESCC continues to be the most prevalent type of esophageal cancer in the East, representing 90% of all cancers in most Asian, African, and Eastern European countries. Clinical management of ESCC remains challenging and the disease presently lacks approved targeted therapeutics.
Recent Developmental Activities in Esophageal Squamous Cell Carcinoma Treatment Landscape
For further information, refer to the detailed Esophageal Squamous Cell Carcinoma Drugs Launch, Esophageal Squamous Cell Carcinoma Developmental Activities, and Esophageal Squamous Cell Carcinoma News, click here for Esophageal Squamous Cell Carcinoma Ongoing Clinical Trial Analysis
Esophageal Squamous Cell Carcinoma Emerging Drugs Profile
Tislelizumab (BGB-A317) is a humanized IgG4 anti–PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug candidate produced from BeiGene’s immuno-oncology biologic program, and we believe it could serve as a key element of our immuno-oncology combination platform. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. Currently, it is in Phase III stage of clinical trial evaluation to treat Esophageal Squamous Cell Carcinoma.
Serplulimab (novel anti-PD-1 mAb) is the first innovative monoclonal antibody (mAb) developed by Henlius. Shanghai Henlius Biotech, announced that the phase 3 clinical study ASTRUM-007 of HANSIZHUANG (serplulimab) independently developed by the company in combination with chemotherapy as a first-line treatment for patients with locally advanced/metastatic esophageal squamous cell carcinoma (ESCC), met the co-primary endpoints of progression-free survival (PFS) and overall survival (OS) in a planned interim analysis, evaluated by the Independent Data Monitoring Committee (IDMC).
Esophageal Squamous Cell Carcinoma Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Esophageal Squamous Cell Carcinoma. The companies which have their Esophageal Squamous Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, BeiGene.
Find out more about the Esophageal Squamous Cell Carcinoma Pipeline Segmentation, Therapeutics Assessment, and Esophageal Squamous Cell Carcinoma Emerging Drugs @ Esophageal Squamous Cell Carcinoma Treatment Landscape
Scope of the Esophageal Squamous Cell Carcinoma Pipeline Report
Dive deep into rich insights for drugs for Esophageal Squamous Cell Carcinoma Pipeline Companies and Therapies, click here @ Esophageal Squamous Cell Carcinoma Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Esophageal Squamous Cell Carcinoma Mergers and acquisitions, Esophageal Squamous Cell Carcinoma Licensing Activities @ Esophageal Squamous Cell Carcinoma Recent Trends, and Future Perspectives
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/